Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients
Open Access
- 5 April 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 5722
Abstract
Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) in the NS5A region impair the efficacy of NS5A inhibitors. In this study, we evaluated the characteristics of the novel RASs observed in treatment-failure patients, A92K and a deletion at P32 (P32del), and the susceptibility of viruses with these RASs to various anti-HCV reagents by using JFH-1 based recombinant HCV with NS5A from a genotype 1b Con1 strain (JFH1/5ACon1). We introduced A92K or P32del solely or in combination with Q24K, L28M, R30Q or L31F into the NS5A of JFH1/5ACon1. Viruses harboring R30Q/A92K showed high extracellular core antigens and infectivity titers, whereas the other viruses with RASs showed low replication levels and infectivity titers. All the viruses with A92K or P32del were markedly resistant to ledipasvir, velpatasvir and elbasvir. Interestingly, viruses with R30Q/A92K were more susceptible to grazoprevir than viruses without RAS. All the viruses had a similar susceptibility to ribavirin and sofosbuvir. In conclusion, combination RASs R30Q/A92K enhanced virus production whereas other RASs impaired virus replication. Both A92K and P32del conferred severe resistance even to second generation NS5A inhibitors. However, these viruses were susceptible to grazoprevir, ribavirin and sofosbuvir. Thus, combination regimens with these reagents may eradicate viruses harboring A92K or P32del.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP18fk0210002, JP18fk0210025, JP18fk0210021))
This publication has 46 references indexed in Scilit:
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infectionHepatology, 2014
- NS5A inhibitors in the treatment of hepatitis CJournal of Hepatology, 2013
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor DaclatasvirAntimicrobial Agents and Chemotherapy, 2013
- Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevirJournal of Hepatology, 2013
- Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052Journal of Virology, 2011
- Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2Biochemical and Biophysical Research Communications, 2011
- Association of Hepatitis C Virus Replication Complexes with Microtubules and Actin Filaments Is Dependent on the Interaction of NS3 and NS5AJournal of Virology, 2008
- NS3 Helicase Domains Involved in Infectious Intracellular Hepatitis C Virus Particle AssemblyJournal of Virology, 2008
- CD81 Expression Is Important for the Permissiveness of Huh7 Cell Clones for Heterogeneous Hepatitis C Virus InfectionJournal of Virology, 2007
- Cell culture and infection system for hepatitis C virusNature Protocols, 2006